Novartis Drug Jakavi(TM) Recommended by CHMP for EU Approval to Treat Patients

Novartis drug Jakavi(TM) recommended by CHMP for EU approval to treat patients

Filed under: drug treatment news articles

Novartis International AG / Novartis drug Jakavi(TM) recommended by CHMP for EU approval to treat patients with the life-threatening blood cancer myelofibrosis . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the …
Read more on Reuters

 

Nadia Lockyer resigns as Alameda County supervisor

Filed under: drug treatment news articles

Battling addiction and the humiliation of a highly publicized altercation in a Newark hotel room with a former lover she met in a rehab program, Alameda County Supervisor Nadia Lockyer abruptly resigned Friday. Despite Lockyer's tumultuous last few …
Read more on San Francisco Chronicle

 

Novartis confirms positive benefit-risk profile of GilenyaR following CHMP

Filed under: drug treatment news articles

The changes follow the Article 20 review by the EMA announced in January 2012. In the European Union, all MS patients initiating treatment with Gilenya should have an electrocardiogram (ECG) and a blood pressure measurement prior to the first dose of …
Read more on Reuters

 

News Novartis Drug Jakavi(TM) Recommended By CHMP For EU Approval To Treat Patients With The Life-threatening Blood Cancer …
Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU approved JAK inhibitor developed to treat patients with myelofibrosis, a rare blood cancer Patients with myelofibrosis experience severe … Read News